Concepedia

Malte Peters

MP

Statistics

Publications

12

Citations

4.3K

H-Index

12

Active since

2000

Affiliations

Novartis (Switzerland)(Current)

Ontario Institute for Cancer Research

University of Toronto

Princess Margaret Cancer Centre

University of Pennsylvania

Malte Peters is an author at Novartis (Switzerland) specializing in medicine, oncology, and molecular oncology.

Publications per year

2000–2020

12

Publications

12

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

Garrett M. Frampton, Siraj M. Ali, Mark R. Rosenzweig et al. · Cancer Discovery · 2015 · 796 citations · Full text

, , +16

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Johanna C. Bendell, Jordi Rodón, Howard A. Burris et al. · Journal of Clinical Oncology · 2011 · 686 citations · Full text

, , +14

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

Paolo A. Ascierto, Dirk Schadendorf, Carola Berking et al. · The Lancet Oncology · 2013 · 644 citations

, , +13

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

Dejan Juric, Pau Castel, Malachi Griffith et al. · Nature · 2014 · 581 citations · Full text

, , +12

DJ-1, a novel regulator of the tumor suppressor PTEN

Raymond H. Kim, Malte Peters, YingJu Jang et al. · Cancer Cell · 2005 · 545 citations · Full text

, , +13

1–5 of 12